APIMEDS PHARMACEUTICALS US, INC. Proceeds from Notes Payable
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Proceeds from Notes Payable of $5.97 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2026-08-14
- APIMEDS PHARMACEUTICALS US, INC. proceeds from notes payable for the quarter ending 2025-12-31 was $100.00.
- APIMEDS PHARMACEUTICALS US, INC. proceeds from notes payable for the quarter ending 2025-09-30 was -$323.32K, a 315.55% decline year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. proceeds from notes payable for the quarter ending 2025-06-30 was $323.32K.
- APIMEDS PHARMACEUTICALS US, INC. proceeds from notes payable for the quarter ending 2025-03-31 was $250.00K.
- APIMEDS PHARMACEUTICALS US, INC. proceeds from notes payable for fiscal 2025 was $250.10K, a 0.04% increase from fiscal 2024.
- APIMEDS PHARMACEUTICALS US, INC. proceeds from notes payable for fiscal 2024 was $250.00K.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 6 month as first filed | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $5.97M 10-Q · filed 2026-08-14 | ||||
| 2025-12-31 | $100.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | -$323.22K derived: sum of 2 quarters · filed 2026-05-04 | $100.00 derived: sum of 3 quarters · filed 2026-08-14 | $250.10K 10-K · filed 2026-05-04 | |
| 2025-09-30 | -$323.32K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-14 | $250.00K 10-Q · filed 2025-11-12 | $250.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $323.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $573.32K 10-Q · filed 2026-08-14 | $250.00K 10-Q · filed 2025-08-19 | $573.32K derived: sum of 3 quarters · filed 2026-08-14 | $723.32K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $250.00K 10-Q · filed 2025-05-20 | $250.00K derived: sum of 2 quarters · filed 2026-05-04 | $400.00K derived: sum of 3 quarters · filed 2026-05-04 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | $150.00K derived: sum of 2 quarters · filed 2026-05-04 | $250.00K 10-K · filed 2026-05-04 | ||
| 2024-09-30 | $150.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $250.00K 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $100.00K 10-Q · filed 2025-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |